News for Atossa Therapeutics Inc (YAG2.MU)

4 Biotech Penny Stocks To Watch Heading Into March 2021 Like any good investor, the key to picking penny stocks to buy is a proper balance between speculation ...

List Of Penny Stocks To Watch If Biotech Is Your Focus In Q1 When it comes to penny stocks, traders look for volatile sectors & industries. One of the more vol...

GameStop Corp. capped another day of heavy losses, pushing its collapse past 80% this week as retail traders flocked to other corners of the stock market such as small drug developers. The video-game retailer tumbled 42% on Thursday to $53.50, erasing nearly $30 billion in market value. Trading…

3 Penny Stocks to Buy With Bullish Analyst Ratings While Covid has helped bring a new focus to biotech penny stocks, there are more reasons why interest in thi...

Will These Biotech Penny Stocks Continue to See Bullish Momentum? In the past twelve months, biotech penny stocks have risen to fame alongside the coronavirus ...

Are These Biotech Names On Your List Of Penny Stocks Right Now? Are you looking for penny stocks to buy right now? If you are, you’re not alone. These cheap ...

So far, in 2021, it seems as though this is the year of penny stocks. Many companies have seen their share prices shoot up in the triple or even quadruple digit...

Today's Daily Dose brings you news about Merck discontinuing its work on COVID-19 vaccines, Moderna advancing its vaccine research to defeat the emerging strains of SARS-CoV-2 virus and AstraZeneca rubbishing German media reports related to AZD1222 vaccine.

Biotech and Energy Penny Stocks Continue to Lead in Gains As January comes to a close, we continue to see high momentum among many of the hottest penny stocks ...

SEATTLE, Jan. 25, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, announced that Dr. Steven C. Quay, President and CEO, will speak as a panelist at the 2021 Precision Medicine World Conference “21st Century Precision Medicine in the Age of COVID-19” to be held virtually January 25-27, 2021. The panel topic is “Development of New SARS-CoV-2 Therapeutics.” The panel begins at 11:30 am PST on January 26, 2021. Dr. Anthony S. Fauci will be the spotlight speaker of the event. Dr. Fauci is the Director of the U.S. National Institute of Allergy and Infectious Diseases and Chief Medical Advisor to the President. The Precision Medicine World Conference, or PMWC, is the largest, original forum for precision medicine. PMWC is an independent conference that attracts recognized authorities and experts across healthcare and biotechnology sectors. The conference showcases practical content that helps close the knowledge gap between different sectors, thereby catalyzing cross-functional collaboration to further adoption of personalized medicine in the clinic. Additional information about PMWC and how to register can be found at https://www.pmwcintl.com/covid/. About Atossa Therapeutics Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19. For more information, please visit www.atossatherapeutics.com. Forward-Looking Statements Disclaimer Statement Forward-looking statements in this press release, which Atossa undertakes no obligation to update, are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including, without limitation, statements regarding the satisfaction of closing conditions relating to the offering and the anticipated use of proceeds from the offering, the risks and uncertainties associated with any variation between interim and final clinical results, actions and inactions by the FDA, the outcome or timing of regulatory approvals needed by Atossa including those needed to commence studies of AT-H201, AT-301 and Endoxifen, lower than anticipated rate of patient enrollment, estimated market size of drugs under development, the safety and efficacy of Atossa’s products, performance of clinical research organizations and investigators, obstacles resulting from proprietary rights held by others such as patent rights, whether reduction in Ki-67 or any other result from a neoadjuvant study is an approvable endpoint for oral Endoxifen, and other risks detailed from time to time in Atossa’s filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time. Company Contact:Atossa Therapeutics, Inc.Kyle Guse, CFO and General CounselOffice: 866 [email protected] Investor Relations Contact:Core IROffice:(516) [email protected]

Gainers TS Innovation Acquisitions Corp. (NASDAQ:TSIA) shares rose 79% to $18.50 in pre-market trading. Latch and TS Innovation Acquisitions dis...

What's moving these stocks in pre-market hours today?.

Should You Buy $1 Penny Stocks Right Now? This has been one of the wildest weeks for penny stocks and we’re not even half-way through January. Not only have ...

Top Penny Stocks For Your Biotech Watch List This Week With 2021 well on its way, the time to find penny stocks to buy is now. But before making any large inve...